Mar. 13 at 11:45 PM
$PROK Just dug into the NCT05018416 history... Management is scrubbing the record for a reason.
1. Management scrubbed the REGEN-007 record, removing Type 1 Diabetes and anemia exclusions. This aligns the data with the FDA's accelerated approval path for Type 2 Diabetes (T2DM).The 85% Efficacy Signal: Removing T1DM "noise" isolates the T2DM subgroup that previously showed an 85% improvement in kidney function decline.
2.Proving Therapy "Toughness", Deleting the anemia barrier suggests the drug is robust enough for complex, late-stage patients, significantly broadening the future market.
3.Commercial Rebranding: Systematic shift from research acronym "REACT" to formal name "rilparencel" signals the transition from lab science to a commercial-ready product.
4. Independent Validation: NephJC (March 9) analyzed rilparencel as a potential "fifth pillar" of kidney treatment alongside SGLT2s and GLP-1s, moving the story toward medical community acceptance.
The stage is set LFG!
